



<http://researchspace.auckland.ac.nz>

### ***ResearchSpace@Auckland***

#### **Copyright Statement**

The digital copy of this thesis is protected by the Copyright Act 1994 (New Zealand).

This thesis may be consulted by you, provided you comply with the provisions of the Act and the following conditions of use:

- Any use you make of these documents or images must be for research or private study purposes only, and you may not make them available to any other person.
- Authors control the copyright of their thesis. You will recognise the author's right to be identified as the author of this thesis, and due acknowledgement will be made to the author where appropriate.
- You will obtain the author's permission before publishing any material from their thesis.

To request permissions please use the Feedback form on our webpage.

<http://researchspace.auckland.ac.nz/feedback>

#### **General copyright and disclaimer**

In addition to the above conditions, authors give their consent for the digital copy of their work to be used subject to the conditions specified on the [Library Thesis Consent Form](#) and [Deposit Licence](#).

#### **Note : Masters Theses**

The digital copy of a masters thesis is as submitted for examination and contains no corrections. The print copy, usually available in the University Library, may contain corrections made by hand, which have been requested by the supervisor.

# **Metabolomic analysis of the interleukin-10-deficient mouse model of Crohn's disease**

Hui-Ming Lin

A thesis submitted in fulfilment of the requirements for the degree  
of Doctor of Philosophy in Molecular Medicine.

The University of Auckland, 2009



## Abstract

Crohn's disease is an inflammatory disorder of the bowel, arising from the dysregulation of intestinal mucosal immunity. The interleukin-10-deficient (IL10<sup>-/-</sup>) mouse develops intestinal inflammation with similar characteristics to Crohn's disease, due to the loss of immune tolerance towards intestinal microbiota. Metabolomic analysis is the study of small molecule metabolites, involving the measurement of large numbers of metabolites in biological samples. The aim of the research was to study the urinary metabolite profile of IL10<sup>-/-</sup> mice by gas chromatography-mass spectrometry metabolomic analysis. A metabolite profile of intestinal inflammation, consisting of 15 metabolites, was discovered by comparing the urinary metabolite profiles of IL10<sup>-/-</sup> and wildtype C57BL/6 mice. Xanthurenic acid and fucose were identified as the main urinary metabolites associated with the early stage of intestinal inflammation. Their levels were increased in IL10<sup>-/-</sup> mice relative to wildtype. Xanthurenic acid levels were attributed to increased tryptophan catabolism which produces kynurenine metabolites that may induce immune tolerance of T-cells towards intestinal microbiota. Plasma levels of kynurenine and 3-hydroxykynurenine were confirmed to be elevated in IL10<sup>-/-</sup> mice. The increased fucose levels may be due to abnormal fucosylation of plasma or intestinal mucosal proteins involved in leukocyte trafficking. Comparisons of the urinary metabolite profiles of IL10<sup>-/-</sup> and wildtype mice also revealed eleven metabolite differences that were unaffected by inflammation severity in IL10<sup>-/-</sup> mice. The main metabolites were glutaric acid, 2-hydroxyglutaric acid and 2-hydroxyadipic acid, which were decreased in IL10<sup>-/-</sup> mice. These eleven metabolite differences may be associated with residual genes from embryonic stem cells of the 129P2 mouse strain used to create the IL10<sup>-/-</sup> mouse, or novel functions of IL10 that are unrelated to inflammation. The metabolite profile of inflammation was not altered in IL10<sup>-/-</sup> mice fed with kiwifruit extracts, consistent with other measures of inflammation which showed that intestinal inflammation was not attenuated by the dietary intervention. The urinary levels of some kiwifruit metabolites differed between IL10<sup>-/-</sup> and wildtype mice, suggesting differences in absorption or intestinal microbial metabolism of these metabolites. Overall, the research demonstrates that metabolomic analysis of IL10<sup>-/-</sup> mice can identify potential biomarkers of intestinal inflammation and provide new insights into the metabolic effects of IL10-deficiency.



# Acknowledgments

I am extremely grateful to my supervisors and colleagues at Plant and Food Research, AgResearch and The University of Auckland for their assistance and contribution to this thesis.

In particular, I would like to acknowledge my supervisors, Daryl Rowan, Nuala Helsby and Lynn Ferguson, for their supervision, guidance and proof-reading; Shelley Edmunds for sharing her experiments and results; Martin Hunt for the countless GC column changes and GCMS technical assistance; Cecilia Deng for creating the TXT2XLSHM software; Nigel Joyce for performing LCMS analysis of the plasma samples; Bev Breslin, Adam Matich, Dan Comesky and Tony McGhie for various technical assistance in the lab; Geoff Lane for discussions on data pre-processing and analysis; Chrissie Butts and Sheridan Martell for the training of mouse handling, preparation of diets and assistance with mouse experiments; Don McNaughton for lending the petri dishes; Matt Barnett, Nicole Roy, Ric Broadhurst, Robert Smith and Bruce Sinclair for the collaboration and assistance in mouse experiments; William Shuotun Zhu and Kelly Armstrong for histology analyses; and Mark McCann and John Rounce for assistance with SAA analysis.

I would also like to thank the Foundation for Research, Science and Technology for funding this work, which is part of the research carried out by Nutrigenomics New Zealand, a collaboration between Plant and Food Research, AgResearch and The University of Auckland.

Last but not least, special thanks to my parents for their love and support.



# Table of contents

<b>Abstract</b>	<b>iii</b>
<b>Acknowledgments</b>	<b>v</b>
<b>Table of contents</b>	<b>vii</b>
<b>Abbreviations</b>	<b>xiii</b>
<b>Chapter 1. Introduction</b>	<b>17</b>
1.1 <i>Overview</i>	17
1.2 <i>Crohn's disease</i>	17
1.2.1 Definition	17
1.2.2 Biochemical assessment	18
1.2.3 Disease etiology	20
1.2.3.1 Genetic and environmental factors	20
1.2.3.2 Dietary factors	21
1.2.3.3 Dysbiosis and pathogens	22
1.2.3.4 Defects in innate immunity	23
1.2.3.5 Defects in adaptive immunity	25
1.2.4 Mouse models	27
1.2.4.1 Chemically-induced mouse models	27
1.2.4.2 Inbred model	27
1.2.4.3 Genetically modified mouse models	28
1.3 <i>The interleukin-10 deficient mouse</i>	29
1.3.1 Interleukin-10	29
1.3.2 Physiology	30
1.3.3 Immunology	32
1.4 <i>Metabolomic analysis</i>	33
1.4.1 Definition	33
1.4.2 Applications	34
1.4.3 Methodology	36
1.4.3.1 Mass spectrometry	36
1.4.3.2 Nuclear Magnetic Resonance	38
1.4.3.3 Other analytical techniques	39
1.5 <i>Thesis justifications</i>	40
1.6 <i>Chapter summary</i>	41

<b>Chapter 2. Method development</b>	<b>43</b>
2.1 <i>Overview</i>	43
2.2 <i>Urine sampling</i>	43
2.2.1 Introduction	43
2.2.2 Experiment and results	45
2.2.3 Conclusions	47
2.3 <i>GCMS analysis of mouse urine</i>	47
2.3.1 Introduction	47
2.3.2 Experiments and results	50
2.3.2.1 Optimisation of chemical derivatisation	50
2.3.2.2 Optimisation of chromatographic separation	55
2.3.2.3 Selection of sample volume	56
2.3.2.4 Assessment of measurement precision and linearity	58
2.3.2.5 Evaluation of urease treatment	62
2.3.2.6 Examination of urine from Alpha-dri cage litter	64
2.3.3 Conclusions	66
2.4 <i>GCMS data pre-processing</i>	66
2.4.1 Introduction	66
2.4.2 Experiments and results	71
2.4.2.1 Experimental datasets	71
2.4.2.2 Comparison of XCMS and MZMine	72
2.4.2.3 Normalisation	75
2.4.3 Conclusions	78
2.5 <i>Chapter summary</i>	78
<b>Chapter 3. Metabolomic identification of metabolite differences</b>	<b>81</b>
3.1 <i>Introduction</i>	81
3.2 <i>Experiment</i>	82
3.2.1 Mice	82
3.2.2 Urine sampling	85
3.2.3 Tissue dissection	85
3.2.4 Assessment of inflammation status	86
3.2.5 GCMS analysis of urine samples	87
3.2.6 GCMS data pre-processing	87
3.2.7 Statistical analyses of GCMS data	87
3.2.8 Metabolite identification	89
3.3 <i>Results</i>	89
3.3.1 Body weight and food intake	89
3.3.2 Inflammation status	90
3.3.3 Urinary metabolite profiles	91
3.3.4 Differential metabolites at all sampling timepoints	99
3.3.5 Differential metabolites at the last three timepoints	103
3.3.6 Intra- and inter-individual variation	106
3.4 <i>Discussion</i>	107

3.5	<i>Conclusions</i>	110
3.6	<i>Chapter summary</i>	111
<b>Chapter 4.</b>	<b>Metabolite profile of intestinal inflammation</b>	<b>113</b>
4.1	<i>Introduction</i>	113
4.2	<i>Experiment</i>	115
4.2.1	Mice	115
4.2.2	Urine sampling	116
4.2.3	Tissue dissection	117
4.2.4	Assessment of inflammation status	117
4.2.5	GCMS analysis and data pre-processing for urine samples	118
4.2.6	Statistical analyses of GCMS data	118
4.2.7	Metabolite identification	119
4.3	<i>Results</i>	120
4.3.1	Body weight and food intake	120
4.3.2	Inflammation status	121
4.3.3	Urinary metabolite profiles	122
4.3.4	Differential urinary metabolites	126
4.3.4.1	Metabolites associated with intestinal inflammation	126
4.3.4.2	Metabolites associated with the IL10 <sup>-/-</sup> genotype	135
4.3.4.3	Metabolites associated with the specific pathogen-free condition	144
4.3.4.4	Metabolites with ambiguous effects	148
4.3.5	Correlation of metabolite levels with inflammation markers	152
4.3.6	Intra- and inter-individual variation	157
4.4	<i>Discussion</i>	160
4.5	<i>Conclusions</i>	163
4.6	<i>Chapter summary</i>	164
<b>Chapter 5.</b>	<b>Metabolomic assessment of dietary intervention</b>	<b>167</b>
5.1	<i>Introduction</i>	167
5.2	<i>Experiment</i>	168
5.3	<i>Results</i>	170
5.3.1	Body weight and food intake	170
5.3.2	Inflammation status	171
5.3.3	Urinary metabolite profiles	172
5.3.4	Metabolites associated with intestinal inflammation	180
5.3.5	Metabolites associated with the IL10 <sup>-/-</sup> genotype	187
5.3.6	Metabolites derived from kiwifruit extracts	189
5.4	<i>Discussion</i>	197
5.5	<i>Conclusions</i>	199
5.6	<i>Chapter summary</i>	199

<b>Chapter 6. Tryptophan metabolism</b>	<b>201</b>
6.1 <i>Introduction</i>	201
6.2 <i>Experiment</i>	205
6.2.1 Preparation of chemical standards	205
6.2.2 Chemical extraction of plasma samples	205
6.2.3 LCMS analysis	206
6.2.4 Statistical analyses	207
6.3 <i>Results</i>	207
6.3.1 Plasma levels of metabolites	207
6.3.2 Correlation with xanthurenic acid and inflammation markers	211
6.4 <i>Discussion</i>	213
6.5 <i>Conclusions</i>	216
6.6 <i>Summary</i>	216
<b>Chapter 7. Final discussion</b>	<b>219</b>
7.1 <i>Overview</i>	219
7.2 <i>Metabolites associated with intestinal inflammation</i>	219
7.2.1 Upregulation of tryptophan metabolism	220
7.2.2 Changes in fucosylation	221
7.2.3 Lysine degradation	222
7.3 <i>Metabolites unaffected by intestinal inflammation</i>	224
7.3.1 Residual genes from the 129P2 mouse strain	224
7.3.2 Lipid metabolism	226
7.3.3 Regulation of sleep	228
7.3.4 Early pathological changes	229
7.4 <i>The IL10<sup>-/-</sup> mouse as a model of Crohn's disease</i>	231
7.5 <i>Problems in metabolomic discovery of biomarkers</i>	232
7.6 <i>Further research</i>	235
7.7 <i>Conclusions</i>	236
7.8 <i>Chapter summary</i>	237
<b>Chapter 8. Protocols</b>	<b>239</b>
8.1 <i>Collecting spot urine samples from mice</i>	239
8.2 <i>GCMS analysis of urine samples</i>	240
8.2.1 Preparation of urease solution	240
8.2.2 Chemical preparation of urine samples	241
8.2.3 Chemical preparation of aqueous extract of AIN76A diet for identifying contamination artifacts	242
8.2.4 GCMS analysis	242
8.3 <i>GCMS data pre-processing</i>	243
8.3.1 Format conversion of datafile	243

8.3.2	Peak detection and alignment with XCMS	244
8.3.3	Removal of artifacts	245
8.3.4	Normalisation of differences between analytical batches	245
8.3.5	Normalisation of differences in urine dilution	246
8.4	<i>Data analysis using R</i>	248
8.4.1	Principal Components Analysis (PCA)	248
8.4.2	Multiple T-tests	250
8.5	<i>Preparation of AIN76A diet</i>	253
8.6	<i>Preparation of bacteria mixture for oral dosing of mice</i>	254
8.7	<i>Measurement of serum amyloid-A (SAA)</i>	258
<b>Chapter 9.</b>	<b>Appendix</b>	<b>261</b>
9.1	<i>Supplementary information for Chapter 3</i>	261
9.2	<i>Supplementary information for Chapter 4</i>	270
9.3	<i>Supplementary information for Chapter 5</i>	284
9.4	<i>Supplementary information for Chapter 6</i>	299
<b>References</b>		<b>301</b>



# Abbreviations

ACMSD	aminocarboxymuconate semialdehyde dehydrogenase
aq	aqueous extract
ATG16L1	autophagy-related 16-like 1
BSTFA	<i>N,O</i> -bis(trimethylsilyl)-trifluoroacetamide
bw	body weight
°C	degree Celcius
CARD15	caspase recruitment domain family, member 15
CCR6	chemokine receptor 6
CEMS	capillary electrophoresis-mass spectrometry
cM	centi-Morgan
conv	conventional housing condition
CRP	C-reactive protein
CV	coefficient of variation
D2HGDH	D-2-hydroxyglutarate dehydrogenase
ddc	dopa decarboxylase
DSS	dextran sodium sulfate
DLG5	discs, large homolog 5 ( <i>Drosophila</i> )
ELISA	enzyme-linked immunosorbent assay
ESR	erythrocyte sedimentation rate
FTIR	Fourier transform-infrared
g	gram
GABA	gamma-aminobutyric acid
GCMS	gas chromatography-mass spectrometry
GHB	gamma-hydroxybutyric acid / 4-hydroxybutyric acid
HEPA	high efficiency particulate air
HLA	human leukocyte antigen
IBD	inflammatory bowel disease
IDO	indoleamine-2,3-dioxygenase
IFN $\gamma$	interferon-gamma
IL1	interleukin-1
IL10	interleukin-10
IL10 <sup>-/-</sup>	interleukin-10-deficient
IL10R	interleukin-10 receptor
IL12	interleukin-12
IL17	interleukin-17
IL1 $\alpha$	interleukin-1-alpha
IL23	interleukin-23

IL23R	interleukin-23 receptor
IL6	interleukin-6
IRGM	immunity-related guanosine triphosphatase
kPa	kiloPascal
LCMS	liquid chromatography-mass spectrometry
MAP	<i>Mycobacterium avium</i> subspecies <i>paratuberculosis</i>
µg	microgram
MHC	major histocompatibility complex
min	minutes
µl	microlitre
ml	millilitre
µm	micron
mm	millimetre
MS	mass spectrometry
MSTFA	<i>N</i> -methyl- <i>N</i> -(trimethylsilyl)-trifluoroacetamide
MUC19	mucin 19
<i>m/z</i>	mass to charge ratio
NFKB	nuclear factor kappa-B
NMR	nuclear magnetic resonance
NOD	nucleotide binding oligomerisation domain protein
OCTN	organic cation transporter
org	organic solvent extract
PBS	phosphate buffered saline
PCA	principal components analysis
PPAR	peroxisome proliferator activated receptor
RAG	recombination activating genes
ret.	retention
R.I.	retention index
RT	retention time
s	seconds
SAA	serum amyloid-A
SAM	senescence accelerated mouse
SCID	severe combined immunodeficiency
SPF	specific pathogen-free
STAT	signal transducer and activator of transcription
Th1	T-helper 1
Th17	T-helper 17
Th2	T-helper 2
TIC	total ion chromatogram
TLR	toll-like receptor
TMS	trimethylsilyl derivative
TNBS	2,4,6-trinitrobenzene sulfonic acid
TNF	tumour necrosis factor-alpha
Tph1	tryptophan 5-monooxygenase 1

Treg	T-regulatory
WT	wildtype
w/w	weight/weight

